Having In the current digital age, the battle against threat attackers continues to escalate. In a world where AI has imploded, cyberbiosecurity is increasingly a priority. Where does AI play a role in your business and how does stronger resilience factor in?
The challenges and opportunities in protecting your biggest asset - your data - will be explored and will help you begin to understand the risks specific to bioscience and our ecosystem.
Join BioNTX in what will be a thought-provoking conversation for the final event in the North Texas cyber trilogy.
Panelists
Upon registering for this event, please be aware that you may be photographed, videotaped, and/or audio-taped. By participating, you grant BioNTX permission to use your image, voice, or survey comments for educational, training, promotional, and communication purposes across all media globally, without restrictions on frequency or duration.
Hazel Chappell, CEO & Founder, ishca health (Moderator)
Having 21 years’ experience with digital transformation in Healthcare, Hazel arrived in America 5 years ago having worked in Ireland, followed by the UK. She is an entrepreneur and businesswoman based in Texas and is CEO and Founder at ishca health Inc.
Introducing a visionary champion at the forefront of disruptive technologies, Hazel is poised to revolutionize America's digital transformation in healthcare. With a profound passion for healthcare and Bioscience with an illustrious track record, she's pioneering innovation with an astute eye for business risk and opportunity.
Hazel’s expertise surpasses traditional boundaries and comes with a focus on AI, change management and cyber resilience in healthcare and bioscience. Hazel actively shapes entrepreneurial initiatives where she currently serves as an executive advisor to help startups by driving operational, management and business excellence propelling their growth and scaling. Through thought leadership and global public speaking engagements, she underscores the critical role of data and the security of it.
Hazel has a diverse and interesting network in America and globally where she has headed up ventures across Europe, to include UK, Sweden, Spain and Ireland in the Banking, Finance and Technical sectors. In today's world where healthcare and bioscience meet technology, she's the guiding light, mitigating risks, capitalizing on opportunities, and bridging the gap between innovation to impact.
Gurshaman Baweja, PhD, MBA, General Partner, Enterprise Venture
Gurshaman is an innovative leader, advisor, angel investor and board member, who combines a technical background and subject matter expertise with business savvy to implement transformative strategies that solve problems, generate operational efficiencies, enhance commercial success, and control risk.
Gurshaman currently advises technology venture capital firms and startups with strategy, sales growth, scaling operations and resiliency. As General Partner of Enterprise Venture Fund (EVF), he is driving acceleration of AI roadmaps in enterprises. Gurshaman is also very actively involved in efforts to transform cancer treatment and care, through influence and awareness.
Previously, in leadership roles at Texas Instruments, including Senior Vice President and Chief Information Officer, Gurshaman brought his expertise in mission-critical issues, including cyber security, scaling of operations, and business continuity, to the board level, advising on strategy to enhance risk posture, optimize supply chain and sales channels, and improve global manufacturing quality and productivity.
Gurshaman holds a Master of Science and Ph.D. in Industrial Engineering from Arizona State University, a Master of Business Administration from Southern Methodist University, and a Bachelor of Science in Mechanical Engineering from Punjab University. He also serves on the Board of Trustees of The Leukemia & Lymphoma Society and the Audit Committee of University of Texas (UT) at Dallas. In his free time, Gurshaman coaches robotics and soccer teams and mentors university STEM students.
Susan Butler, Director of Product Management, Kerv.ai
As the Director of Product Management at Kerv.ai, an AI-powered video technology company, Susan Butler offers a unique viewpoint on the convergence of cybersecurity and biotechnology. With her ISC2 CC certification ("Certified in Cybersecurity"), experience in digital compliance standards, and nonstandard work experience, Susan is uniquely prepared for navigating the complex landscape of cyberbiosecurity.
Her background ranges from running biohacking events (BodyHacking Con) and hacker conferences (ISSW), to Product Management and training neural nets. She believes that privacy and security is important for everyone, infuses the 'hacker mindset' into everything she does, and looks forward to the challenges the new landscape of AI brings to security- particularly in the biotechnology and healthcare fields.
Though Susan hails from Canada originally, she has been largely located in Austin, Texas since the mid 90s, and has family in the DFW area. When she's not nerding out on all things product and security, she enjoys painting, watching movies, and reading sci-fi.
Panna Sharma, CEO & President, Lantern Pharma
Panna Sharma is the President and CEO of Lantern Pharma Inc., a clinical-stage oncology biotech using artificial intelligence (AI) and genomics to innovate the rescue, revitalization, and development of precision cancer therapeutics. As CEO, Panna is responsible for developing Lantern’s strategic vision, and working closely with the venture investors to raise capital that will place the Company at the forefront of using AI and genomics in developing its pipeline of precision therapies.
Prior to joining Lantern in 2018, Panna was the President and CEO of Cancer Genetics, Inc., a provider of genomic and immune-based cancer diagnostics and therapy development services to some of the most prestigious medical institutions and pharma companies in the world. In his capacity as CEO at CGIX, he raised over $100 million in the public and private markets and grew the company from 25 employees in New Jersey to over 250 employees globally across multiple continents. Panna took CGIX public in 2013 and acquired four companies globally that help CGIX deliver on its mission to help personalize cancer treatment.
Panna attended Boston University in the University Professors Program and focused his studies on Philosophy of Science, Neural Networks and Artificial Intelligence. When not focused on the future of biotech, machine learning, emerging technologies, and genomics, Panna can be found with his three children and wife and listening to music, attending sports functions, discussing new and ethical uses of AI, debating language theories and enjoying the vibrant and evolving local food scene.
Have a login? Login Now
{{vm.loginInfo.errorMessage}}
Create an Account
Forgot your Username or Password?
Register as Guest
Address
Phone
{{slot.Name}}
{{ vm.EventInfo.EventSettings.NoShowPolicy }}